BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
4-8 Maple Street, London, England, W1T5HD
Website
www.benevolent.com
No of Employees
248
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BAI (AMS)
Revenue (2022)
$9.1M
-30.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
61.4%
(2022 vs 2021)
Market Cap*
$100.4M
Net Profit Margin (2022)
XYZ
44.4%
(2022 vs 2021)
* As of and is in US$
BenevolentAI Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| BEN2293 (Atopic Dermatitis) | Data foundations |
| BEN8744 (Ulcerative Colitis) | Target identification |
| BEN9160 (Amyotrophic Lateral Sclerosis) | Drug programmes |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company signed a collaboration with Merck to enable Merck to leverage the company’s powerful end-to-end AI platform. |
| 2022 | Contracts/Agreements | In October, the company and AstraZeneca partnered to integrates AstraZeneca’s data into its biomedical Knowledge Graph to rapidly normalise and contextualise a diverse range of external and internal data from numerous sources. |
| 2022 | Acquisitions/Mergers/Takeovers | In April, the company merged with Odyssey Acquisition SA. |
Competitor Comparison
| Key Parameters | BenevolentAI Ltd | Acacia Pharma Group Ltd | 4D Pharma Plc | Aria Pharmaceuticals Inc | Cresset BioMolecular Discovery Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United States of America | United Kingdom |
| City | London | Cheshire | Leeds | Palo Alto | Litlington |
| State/Province | England | England | England | California | Cambridgeshire |
| No. of Employees | 248 | 74 | 95 | - | 46 |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Francois Nader | Chairman | Executive Board | 2023 | - |
| Joerg Moeller, MD, PhD | Director; Chief Executive Officer | Executive Board | 2024 | - |
| Ivan Griffin | Co-Founder; Chief Operating Officer | Executive Board | 2014 | - |
| Anna Fullerton-Batten | Chief People Officer | Executive Board | - | - |
| James Malone | Chief Technology Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward